Regeneron provides business updates and highlights from broad clinical pipeline at the 43rd annual j.p. morgan healthcare conference

Dupixent ® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role eylea hd ® and eylea ® remained the u.s. anti-vegf category leader in 2024; aggregate u.s. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results eylea hd pre-filled syringe (pfs) submission completed; launch expected by mid-2025 libtayo ® exceeded $1 billion in 2024 annual net sales, and becomes the first and only immunotherapy to show a statistically significant clinical benefit as adjuvant therapy in high-risk cutaneous squamous cell carcinoma (cscc) linvoseltamab biologics license application (bla) resubmitted following resolution of third-party manufacturing issues; launch anticipated mid-2025 approximately 40 investigational candidates in industry-leading pipeline cover dozens of disease states with expansive market potential regeneron collaborates with truveta and leading american health systems to massively extend its dna-linked healthcare database to further advance scientific innovation and healthcare delivery   tarrytown, n.y., jan. 13, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today will share corporate progress and highlights from the company's broad and diverse investigational pipeline while presenting at the annual j.p.
REGN Ratings Summary
REGN Quant Ranking